becocalcidiol
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2004 (NCT00373516)
Timeline
2000s
- Jan 1, 2004
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Vitamin D receptorAGONIST
VDR agonist
Chemistry & pharmacology
Loading structure…
SMILES
C=C1[C@H](O)CC(=C/C=C2\CCC[C@]3(C)[C@@H]([C@@H](C)CC)CC[C@@H]23)C[C@H]1O- Mol. weight
- 344.54 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2104955 ↗
Also known as
- 2mbisp
- 2mbisp
- 2mbisp
- 2-methylene-19-nor-(20s)-1 alpha-hydroxy-bishomopregnacalciferol
- becocalcidiol
- becocalcidiol
- becocalcidiol
- dp-006
- dp-006
- qrx-101
- qrx-101
- qrx-101
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00373516 | Phase 2 | Sep 1, 2004 | Quatrx Pharmaceuticals Co |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Quatrx Pharmaceuticals Co | For profit | 1 | 1 | 1 | 2004 |
1 organizations
Page 1 / 1